Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05982795 · ClinicalTrials.gov registry record
Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome
A clinical trial of Cystic Fibrosis, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT05982795: Recruiting study of Cystic Fibrosis, sponsored by Dartmouth-Hitchcock Medical Center.
NCT05982795 is a study of Cystic Fibrosis that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 30 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05982795, a study of Cystic Fibrosis, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn about the effects of a specific cystic fibrosis therapy (Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy) on chronic sinonasal disease. The main questions it aims to answer are: 1. How does this therapy impact bacterial communities in the paranasal sinuses? 2. How does this therapy impact inflammation in the paranasal sinuses and olfactory cleft? 3. How does this therapy impact sense of smell and sinonasal disease burden in individuals with cystic fibrosis? 4. How does this therapy impact disease-specific and general quality of life of individuals with cystic fibrosis? Participants will be asked to provide samples from their nose, complete testing of their sense of smell, and complete surveys about their quality of life and sense of smell in this study. Researchers will compare study results between patients who are currently undergoing Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy and patients who are not currently undergoing therapy.
Primary Outcome
Difference in microbial communities in mucus swabs between cystic fibrosis patients on CFTR-MT and cystic fibrosis patients not on CFTR-MT.
Conditions Studied
Interventions
- OTHER Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge
- OTHER Olfactory Function Testing
- OTHER Survey Completion
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2026-12-01 |
What NCT05982795 shows while recruiting
NCT05982795 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge is the first listed.
NCT05982795 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05982795 about?
NCT05982795 is a clinical study titled "Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome". The goal of this observational study is to learn about the effects of a specific cystic fibrosis therapy (Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy) on chronic sinonasal disease. The main questions it aims to answer are: 1. How does this therapy impact bacterial communit...
What is the current status of trial NCT05982795?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2023-11-08. Estimated completion is 2026-12-01.
What conditions does trial NCT05982795 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT05982795?
The interventions under investigation include: Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge (OTHER), Olfactory Function Testing (OTHER), Survey Completion (OTHER).
Who is sponsoring clinical trial NCT05982795?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05982795 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05982795's enrollment target sits among peer trials
30 113th of 169 higher than 51 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI